Cytotoxic Effect of Prunus Divaricata Ledeb. Extract on Lung Cancer Cells and Determination of Expression Profiles of Genes in the MAP-Kinase Pathway

Year 2023, Volume: 27 Issue: 1, 181 - 188, 28.02.2023

İbrahim Seyfettin Çelik , Ashabil Aygan , Mustafa Çiçek , Yusuf Ziya Kocabaş

https://doi.org/10.16984/saufenbilder.1221057

Abstract

Cherry plum (Prunus divaricata Ledeb.) is a diploid fruit tree that belongs to the Rosaceae family. Anticarcinogenic activity of Prunus divaricata Ledeb. methanol extract was examined in lung cancer cell lines A549 and H1299 as well as in healthy cell line Beas-2b in this study. The changes in the expression levels of the most frequently mutated oncogenes in lung cancer, KRAS, EGFR, BRAF, and PIK3CA were investigated as well. In vitro cytotoxicity assays of P. divaricata Ledeb. fruit methanol extract was conducted by measuring the percentage of viable cells spectrophotometrically using the cell viability identification kit (CVDK) based on the colorimetric method. The AB 7500 Fast RT-PCR device with Sybr Green Master Mix was used to create gene expression profiles, and the Ct values of all genes were assessed by normalizing the Ct value of the housekeeping gene. The methanol extract of P. divaricata Ledeb. fruit was found to have a cytotoxic effect on A549 and H1299 cancer cell lines at 20 mg/ml, but not on the Beas-2b cell line at these concentrations. By reducing proliferation, low KRAS and PIK3CA gene expression caused the cells to undergo apoptosis. The methanol extract of P. divaricata Ledeb. fruit has been found to inhibit the development of cancerous cells while promoting the proliferation of healthy cells. We believe it does this through the apoptotic pathway by regulating gene expression levels in oncogenes via the MAP-Kinase pathway.

Keywords

Anticancer, gene expression, P. divaricata subs P. divaricata Ledeb.

References

• [1] M. Yu, B. Qi, W. Xiaoxiang, J. Xu, X. Liu, “Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-kappaB pathway”, Biomed., Pharmacother, vol. 90, pp. 677–685, 2017.
• [2] S. Meschini, E. Pellegrini, M. Condello, G. Occhionero, S. Delfine, G. Condello, F. Mastrodonato, “Cytotoxic and Apoptotic Activities of Prunus spinosa Trigno Ecotype Extract on Human Cancer Cells”, Molecules. vol. 22, no. 9, p. 1578, 2017.
• [3] A. A. Dönmez, Ş. Yıldırımlı , "Taxonomy of the Genus Prunus L. (Rosaceae) in Turkey", Turkish Journal of Botany, vol. 24, no. 3, pp. 187-202, 2000
• [4] M. H. Yu, H. G. Im, H.I. Kim, I. S. Lee. “Induction of apoptosis by immature plum in human hepatocellular carcinoma”, Journal of Medicinal Food, vol. 12, no. 3, pp. 518-527, 2009.
• [5] W. Li, M. Cheng, W. Zhang, R. He, H. Yang, “New Insights into the Mechanisms of Polyphenol from Plum Fruit Inducing Apoptosis in Human Lung Cancer A549 Cells Via PI3K/AKT/FOXO1 Pathway”, Plant Foods for Human Nutrition, vol. 76, no. 1, pp. 125-132, 2021.
• [6] J. Y. Fang, B. C. Richardson, “The MAPK signalling pathways and colorectal cancer”, The Lancet Oncology, vol. 6, no. 5, pp. 322-327, 2005.
• [7] N. Karakas, M. E. Okur, I. Ozturk, S. Ayla, A. E. Karadag, D. Ç. Polat, “Antioxidant Activity of Blackthorn (Prunus spinosa L.) Fruit Extract and Cytotoxic Effects on Various Cancer Cell Lines”, Medeniyet Medical Journal, vol. 34, no. 3, pp. 297-304, 2019. [8] E. O. Igwe, K. E. Charlton. “A Systematic Review on the Health Effects of Plums (Prunus domestica and Prunus salicina)”, Phytotherapy Research, vol. 30, no. 5, pp. 701-731, 2016.
• [9] Z.W. Jones, R. Leander, V. Quaranta, L. A. Harris, D. R. Tyson. “A drift-diffusion checkpoint model predicts a highly variable and growth-factor-sensitive portion of the cell cycle G1 phase”, PLoS One, vol. 13, no. 2, p. e0192087, 2018
• [10] H. Abbaszadeh, B. Keikhaei, S. Mottaghi, “A review of molecular mechanisms involved in anticancer and antiangiogenic effects of natural polyphenolic compounds”, Phytotherapy Research, vol. 33, no. 8, pp. 2002-2014, 2019
• [11] T. Zhang, B. Wan, Y. Zhao, C. Li, H. Liu, T. Lv, P. Zhan, Y. Song, “Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment”, Translational Lung Cancer Research, vol. 8, no. 3, pp. 302-316, 2019.
• [12] S. I. Rothschild, “Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK”, Cancers (Basel), vol. 7, no. 2, pp. 930-949, 2015.
• [13] G. W. M. Millington, “Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54)”, Clinical and Experimental Dermatology, vol. 38, no. 2, pp. 222-223, 2013.
• [14] T. Ersahin, N. Tuncbag, R. Çetin-Atalay “The PI3K/AKT/mTOR interactive pathway”, Molecular BioSystems, vol. 11, no. 7, pp. 1946-1954, 2015.
• [15] V. Ludovini, F. Bianconi, L. Pistola, R. Chiari, V. Minotti, R. Colella, D. Giuffrida, F. R. Tofanetti, A. Siggillino, A. Flacco, E. Baldelli, D. Iacono, M. G. Mameli, A. Cavaliere, L. Crinò, “Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer”, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 6, no. 4, pp. 707–715, 2011.